
Xinxin Ding
- Head, Pharmacology and Toxicology
- Professor, Pharmacology and Toxicology
- Professor, BIO5 Institute
- Member of the Graduate Faculty
- Professor, Cancer Biology - GIDP
- Professorship, R Ken and Donna Coit
Contact
- (520) 626-9906
- Pharmacy, Rm. 345G
- Tucson, AZ 85721
- xding@arizona.edu
Bio
No activities entered.
Interests
No activities entered.
Courses
2025-26 Courses
-
Contemp Topics Drug Discovery
PCOL 530 (Fall 2025) -
General+Systems Tox
EHS 535 (Fall 2025) -
General+Systems Tox
PCOL 535 (Fall 2025) -
Introduction to Pharmacology
PHSC 501 (Fall 2025) -
Leadership in Pharmacy
PHPR 833 (Fall 2025) -
Research
PCOL 900 (Fall 2025)
2024-25 Courses
-
Directed Research
PCOL 792 (Spring 2025) -
Directed Rsrch
MCB 492 (Spring 2025) -
Dissertation
PCOL 920 (Spring 2025) -
Drug Metabolism + Dsptn
CBIO 550 (Spring 2025) -
Drug Metabolism + Dsptn
PCOL 550 (Spring 2025) -
Independent Study
PCOL 699 (Spring 2025) -
Intro to Pharmacology/MedChem
PCOL 824 (Spring 2025) -
Research Conference
PCOL 695A (Spring 2025) -
Contemp Topics Drug Discovery
CBIO 530 (Fall 2024) -
Contemp Topics Drug Discovery
PCOL 530 (Fall 2024) -
Contemp Topics Drug Discovery
PHSC 530 (Fall 2024) -
Directed Research
PCOL 792 (Fall 2024) -
Dissertation
PCOL 920 (Fall 2024) -
General+Systems Tox
PCOL 535 (Fall 2024) -
Introduction to Pharmacology
PCOL 501 (Fall 2024) -
Introduction to Pharmacology
PHSC 501 (Fall 2024) -
Leadership in Pharmacy
PHPR 833 (Fall 2024)
2023-24 Courses
-
Dissertation
PCOL 920 (Spring 2024) -
Drug Metabolism + Dsptn
PCOL 550 (Spring 2024) -
Honors Thesis
PCOL 498H (Spring 2024) -
Intro to Pharmacology/MedChem
PCOL 824 (Spring 2024) -
Research Conference
PCOL 695A (Spring 2024) -
Dissertation
PCOL 920 (Fall 2023) -
General+Systems Tox
CBIO 535 (Fall 2023) -
General+Systems Tox
PCOL 535 (Fall 2023) -
Honors Thesis
PCOL 498H (Fall 2023) -
Introduction to Pharmacology
PCOL 501 (Fall 2023) -
Research
BIOC 900 (Fall 2023) -
Research Conference
PCOL 695A (Fall 2023)
2022-23 Courses
-
Directed Research
MCB 792 (Spring 2023) -
Dissertation
PCOL 920 (Spring 2023) -
Drug Metabolism + Dsptn
PCOL 550 (Spring 2023) -
Intro to Pharmacology/MedChem
PCOL 824 (Spring 2023) -
Research
PCOL 900 (Spring 2023) -
Research Conference
PCOL 695A (Spring 2023) -
Dissertation
PCOL 920 (Fall 2022) -
General+Systems Tox
CBIO 535 (Fall 2022) -
General+Systems Tox
PCOL 535 (Fall 2022) -
Independent Study
PCOL 399 (Fall 2022) -
Introduction to Pharmacology
PCOL 501 (Fall 2022) -
Introduction to Pharmacology
PHSC 501 (Fall 2022) -
PharmTox Journal Club
PCOL 595A (Fall 2022) -
Research
PCOL 900 (Fall 2022) -
Research Conference
PCOL 695A (Fall 2022)
2021-22 Courses
-
Dissertation
PCOL 920 (Spring 2022) -
Drug Metabolism + Dsptn
CBIO 550 (Spring 2022) -
Drug Metabolism + Dsptn
PCOL 550 (Spring 2022) -
Intro to Pharmacology/MedChem
PCOL 824 (Spring 2022) -
Research
PCOL 900 (Spring 2022) -
Research Conference
PCOL 695A (Spring 2022) -
Dissertation
PCOL 920 (Fall 2021) -
General+Systems Tox
PCOL 535 (Fall 2021) -
Introduction to Pharmacology
PCOL 501 (Fall 2021) -
Introduction to Pharmacology
PHSC 501 (Fall 2021) -
Research
PCOL 900 (Fall 2021) -
Research Conference
PCOL 695A (Fall 2021)
2020-21 Courses
-
Drug Dsptn+Metabolism
CBIO 550 (Spring 2021) -
Drug Dsptn+Metabolism
PCOL 550 (Spring 2021) -
Intro to Pharmacology/MedChem
PCOL 824 (Spring 2021) -
Research
PCOL 900 (Spring 2021) -
Research Conference
PCOL 695A (Spring 2021) -
Clinical Pathophysiology I
PCOL 838A (Fall 2020) -
Directed Research
MCB 792 (Fall 2020) -
Intro Molecular Therapeutics
CBIO 530 (Fall 2020) -
Intro Molecular Therapeutics
CHEM 530 (Fall 2020) -
Intro Molecular Therapeutics
PCOL 530 (Fall 2020) -
Intro Molecular Therapeutics
PHSC 530 (Fall 2020) -
Introduction to Pharmacology
PCOL 501 (Fall 2020) -
Introduction to Pharmacology
PHSC 501 (Fall 2020) -
Research
PCOL 900 (Fall 2020) -
Research Conference
PCOL 695A (Fall 2020)
2019-20 Courses
-
Drug Dsptn+Metabolism
PCOL 550 (Spring 2020) -
Intro to Pharmacology/MedChem
PCOL 824 (Spring 2020) -
Research
PCOL 900 (Spring 2020) -
Research Conference
PCOL 695A (Spring 2020) -
Clinical Pathophysiology I
PCOL 838A (Fall 2019) -
Honors Independent Study
PCOL 499H (Fall 2019) -
Introduction to Research
MCB 795A (Fall 2019) -
Research Conference
PCOL 695A (Fall 2019)
2018-19 Courses
-
Dissertation
PHSC 920 (Spring 2019) -
Drug Dsptn+Metabolism
CBIO 550 (Spring 2019) -
Drug Dsptn+Metabolism
PCOL 550 (Spring 2019) -
Intro to Pharmacology/MedChem
PCOL 824 (Spring 2019) -
Clinical Pathophysiology I
PCOL 838A (Fall 2018) -
Introduction to Research
MCB 795A (Fall 2018) -
Pharmacology I
PCOL 571A (Fall 2018) -
Pharmacology I
PCOL 871A (Fall 2018)
2017-18 Courses
-
Drug Dsptn+Metabolism
CBIO 550 (Spring 2018) -
Drug Dsptn+Metabolism
PCOL 550 (Spring 2018)
Scholarly Contributions
Journals/Publications
- Zhang, Q. Y., Winkle, L. V., Kovalchuk, N., & Ding, X. (2020). Contribution of Pulmonary CYP-mediated Bioactivation of Naphthalene to Airway Epithelial Injury in the Lung.. Toxicological sciences : an official journal of the Society of Toxicology, 177(2), 334-346. doi:10.1093/toxsci/kfaa114More infoPrevious studies have established that cytochrome P450 enzymes (CYPs) in both liver and lung are capable of bioactivating naphthalene (NA), an omnipresent air pollutant and possible human carcinogen, in vitro and in vivo. The aim of this study was to examine the specific contribution of pulmonary CYPs in airway epithelial cells to NA-induced airway toxicity. We used a lung-Cpr-null mouse model, which undergoes doxycycline-induced, Cre-mediated deletion of the Cpr (a redox partner of all microsomal CYPs) gene specifically in airway epithelial cells. In 2-month-old lung-Cpr-null mice, Cpr deletion occurred in 75%-82% of epithelial cells of conducting airways. The extent of NA-induced acute lung toxicity (as indicated by total protein concentration and lactate dehydrogenase activity in bronchoalveolar lavage fluid collected at 24-h after initiation of a 4-h, nose-only, 10-ppm NA inhalation exposure) was substantially lower (by 37%-39%) in lung-Cpr-null mice, compared with control littermates. Moreover, the extent of cellular proliferation (as indicated by 5-bromo-2'-deoxyuridine incorporation) was noticeably lower in both proximal and distal airways (by 59% and 65%, respectively) of NA-treated lung-Cpr-null mice, compared with control littermates, at 2-day post-NA inhalation exposure. A similar genotype-related difference in the extent of postexposure cell proliferation was also observed in mice exposed to NA via intraperitoneal injection at 200 mg/kg. These results directly validate the hypothesis that microsomal CYP enzymes in airway epithelial cells play a large role in causing injury to airway epithelia following exposure to NA via either inhalation or intraperitoneal route.
- Buchholz, B. A., Carratt, S. A., Kuhn, E. A., Collette, N. M., Ding, X., & Van, W. (2019). Naphthalene DNA adduct formation and tolerance in the lung. NUCLEAR INSTRUMENTS & METHODS IN PHYSICS RESEARCH SECTION B-BEAM INTERACTIONS WITH MATERIALS AND ATOMS, 438, 119-123.
- Carratt, S. A., Hartog, M., Buchholz, B. A., Kuhn, E. A., Collette, N. M., Ding, X., & Van, W. (2019). Naphthalene genotoxicity: DNA adducts in primate and mouse airway explants. TOXICOLOGY LETTERS, 305, 103-109.
- Carratt, S. A., Kovalchuk, N., Ding, X., & Van, W. (2019). Metabolism and Lung Toxicity of Inhaled Naphthalene: Effects of Postnatal Age and Sex. TOXICOLOGICAL SCIENCES, 170(2), 536-548.
- Fan, X., Li, H., Ding, X., & Zhang, Q. (2019). Contributions of Hepatic and Intestinal Metabolism to the Disposition of Niclosamide, a Repurposed Drug with Poor Bioavailability. DRUG METABOLISM AND DISPOSITION, 47(7), 756-763.
- Hartog, M., Zhang, Q., & Ding, X. (2019). Role of Mouse Cytochrome P450 Enzymes of the Cyp2abfgs Subfamilies in the Induction of Lung Inflammation by Cigarette Smoke Exposure. TOXICOLOGICAL SCIENCES, 172(1), 123-131.
- Kovalchuk, N., Zhang, Q., Kelty, J., Van, W. L., & Ding, X. (2019). Toxicokinetic Interaction between Hepatic Disposition and Pulmonary Bioactivation of Inhaled Naphthalene Studied Using Cyp2abfgs-Null and CYP2A13/2F1-Humanized Mice with Deficient Hepatic Cytochrome P450 Activity. DRUG METABOLISM AND DISPOSITION, 47(12), 1469-1478.
- Wang, H., Qin, M., Liu, R., Ding, X., Chen, I., & Jiang, Y. (2019). Characterization of A Bifunctional Synthetic RNA Aptamer and A Truncated Form for Ability to Inhibit Growth of Non-Small Cell Lung Cancer. SCIENTIFIC REPORTS, 9.
- Zhang, Y. u., Shen, B., Guan, X., Qin, M., Ren, Z., Ma, Y., Dai, W., Ding, X., & Jiang, Y. (2019). Safety and efficacy of ex vivo expanded CD34(+) stem cells in murine and primate models. STEM CELL RESEARCH & THERAPY, 10.